NCT05727761View on ClinicalTrials.gov

Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

July 28, 2026

Study Completion Date

July 28, 2026

Conditions
Oral Leukoplakia
Interventions
DRUG

pioglitazone-metformin

Treatment with pioglitazone-metformin (15mg/500mg) twice a day for 12 weeks

Trial Locations (1)

55455

RECRUITING

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER